Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of ImmunityBio in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.29 EPS.

A number of other equities research analysts also recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a report on Friday, February 28th. BTIG Research assumed coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.19.

ImmunityBio Trading Down 3.1 %

Shares of NASDAQ IBRX opened at $2.82 on Monday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -3.07 and a beta of 0.82. The business has a 50 day simple moving average of $3.06 and a 200-day simple moving average of $3.68.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $8.74 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after purchasing an additional 790,408 shares during the period. Barclays PLC boosted its position in ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after acquiring an additional 202,248 shares during the period. Handelsbanken Fonder AB boosted its position in ImmunityBio by 71.2% during the 4th quarter. Handelsbanken Fonder AB now owns 92,300 shares of the company’s stock worth $236,000 after acquiring an additional 38,400 shares during the period. Stephens Inc. AR acquired a new position in ImmunityBio during the 4th quarter worth $26,000. Finally, SBI Securities Co. Ltd. acquired a new position in ImmunityBio during the 4th quarter worth $58,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.